Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
GLUE compared with SVRA: revenue, margins and what each company keeps, and the suppliers and customers both name
GLUE
Monte Rosa Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SVRA
Savara Inc
Change
Mkt cap
Revenue
Revenue
vs
Compare
GLUE
Monte Rosa Therapeutics, Inc.
vs
SVRA
Savara Inc
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
GLUE
0 of 4
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±15.6%
▲
+0.64%
×0.04
May 7 '26
±25.6%
▼
−2.84%
×0.11
Q1 FY26
±24.5%
▼
−1.96%
×0.08
Nov 6 '25
±18.2%
▲
+5.69%
×0.31
SVRA
No earnings history for SVRA.
= implied
GLUE realized, solid
SVRA realized, hatched
One scale, both sides: full bar = 26%
× = |realized| ÷ implied
Source: market data
GLUE
Monte Rosa Therapeutics, Inc.
Change
10.54
▼
−2.04%
Mkt cap
$918.0M
Revenue
$9M
Q2 FY26
Revenue
$124M
FY25
SVRA
Savara Inc
Change
4.69
▼
−2.70%
Regular session
Nov 2 '26
Mkt cap
$990.3M
Revenue
—
Revenue
—
vs
Compare
Regular session
Nov 2 '26
GLUE
Monte Rosa Therapeutics, Inc.
vs
SVRA
Savara Inc
10.54
▼
−2.04%
Price
4.69
▼
−2.70%
$918.0M
Mkt cap
$990.3M
Q2 FY26
$9M
Revenue
—
FY25
$124M
Revenue
—
Change
Change
GLUE
10.54
▼
−2.04%
vs
SVRA
4.69
▼
−2.70%
Regular session
Nov 2 '26